Evidence map›Paper›PMID 42286309›Full record

ArticleCellular oncology (Dordrecht, Netherlands)2026

Microchromosome maintenance protein 2 is essential in immune infiltration-correlated prognosis of multiple myeloma patients by regulating cell cycle.

Aziguli Maihemaiti, Lu Tang, Hui Zhou, Zhao Xu, Jifeng Jiang, Jianguo Fang, Yifeng Sun

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cellular oncology (Dordrecht, Netherlands), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Aziguli Maihemaiti *Department of Lymphoma, The Affiliated Cancer Hospital of Xinjiang Medical University, Urumqi, China.
Lu Tang *Department of Echocardiography, Zhongshan Hospital, Fudan University, Shanghai, China.
Hui Zhou *Department of Nursing, Shanghai Ninth People's Hospital, Shanghai JiaoTong University School of Medicine, Shanghai, China.
Zhao XuDepartment of Hematology, Xinhua Hospital, Shanghai JiaoTong University School of Medicine, Shanghai, China.
Jifeng JiangDepartment of Hematology, Huadong Hospital, Fudan University, Shanghai, China.
Jianguo FangDepartment of Hematology, Shanghai Ninth People's Hospital, Shanghai JiaoTong University School of Medicine, 639 Zhizaoju Road, Shanghai, 200011, China.
Yifeng SunDepartment of Hematology, Shanghai Ninth People's Hospital, Shanghai JiaoTong University School of Medicine, 639 Zhizaoju Road, Shanghai, 200011, China. 16111210013@fudan.edu.cn.

Funding

Shanghai Science and Technology Commission Yangfan Program Project 21YF1406200the National Natural Science Foundation of China 82100216
6 · The paper itself

Abstract

purposeMultiple myeloma (MM) is a common hematological malignancy, while the prognostic value of tumor-infiltrating immune cells in MM remains elusive. This study aimed to construct an immune-related prognostic model and identify potential therapeutic targets for MM.

methodsRNA-seq and clinical data of 751 newly diagnosed MM patients were analyzed. LASSO regression was applied to establish an immune pathway-based prognostic model for patient risk stratification. WGCNA was used to screen hub genes, and in vitro and in vivo experiments validated gene functions and therapeutic effects.

resultsFive immune cell pathways were significantly correlated with MM prognosis. MCM2 was identified as the key hub gene associated with risk scores. MCM2 knockdown induced G2-phase cell cycle arrest and suppressed MM proliferation both in vitro and in vivo. Moreover, MCM2 inhibition enhanced the antitumor efficacy of PD1/PDL1 inhibitor BMS1, and CDK inhibitor PHA767491 sensitized MM to immunotherapy.

conclusionThe immune-based model reliably predicts MM prognosis. MCM2 serves as a vital prognostic biomarker. Targeting MCM2 combined with PD1/PDL1 and CDK inhibitors represents a promising therapeutic strategy for MM.

Indexed as

Cell CycleMinichromosome Maintenance Complex Component 2Multiple MyelomaAnimalsBiomarkers, TumorCell Line, TumorCell ProliferationFemaleGene Expression Regulation, NeoplasticHumansMaleMicePrognosisBiomarkers, TumorMCM2 protein, humanMinichromosome Maintenance Complex Component 2Cell cycleImmune infiltrationMicrochromosome maintenance protein 2Multiple myeloma

Identifiers

PMID42286309
PMCPMC13486458

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.